Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive-compulsive disorder

International Journal of Neuropsychopharmacology

Volumn 6, Issue 1, 2003, Pages 13-21

  Zghoul, Tarek ^a   Blier, Pierre ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT1A receptors; 5 HT2 receptors; Hallucinogens; Hippocampus; Orbitofrontal cortex

Indexed keywords

CHLORAL HYDRATE; LYSERGIDE; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; HALLUCINOSIS; HIPPOCAMPUS; IONTOPHORESIS; MALE; NERVE CELL; NERVE CONDUCTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORBITAL CORTEX; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID AGONISTS; HALLUCINOGENS; IONTOPHORESIS; LYSERGIC ACID DIETHYLAMIDE; MALE; NEURAL INHIBITION; NEURONS; QUISQUALIC ACID; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 0037346676     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145702003218     Document Type: Article

References (39)

1. Aghajanian GK, Marek GJ (1999). Serotonin and hallucinogens. Neuropsychopharmacology 21 (2 Suppl. 2), 16S-23S.
2. Andrade R, Malenka RC, Nicoll RA (1986). A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science 234, 1261-1265.
3. Andrade R, Nicoll RA (1987). Novel anxiolytics discriminate between post synaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn Schmiedeberg's Archives of Pharmacology 336, 5-10.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn (pp. 417-420). Washington, DC: American Psychiatric Association.
5. Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE (1987). Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Archives of General Psychiatry 44, 211-218.
6. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, Phelps ME (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry 49, 681-689.
7. Bergqvist PB, Bouchard C, Blier P (1999a). Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biological Psychiatry 45, 164-174.
8. 2 receptors in the rat orbitofrontal cortex: an in vivo electrophysiological study. Psychopharmacology 143, 89-96.
9. Blier P, de Montigny C (1983). Effects of quipazine on pre- and postsynaptic serotonin receptors; single cell studies in the rat CNS. Neuropharmacology 22, 495-499.
10. 1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1, 470-480.
11. Blier P, de Montigny C (1990). Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: single-cell recording studies. Journal of Clinical Psychopharmacology 10 (Suppl. 3), 13S-20S.
12. Blier P, de Montigny C (1999). Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 (2 Suppl.), 91S-98S.
13. 1A receptors in the dorsal raphe and hippocampus. II. Effect of pertussis and cholera toxins. Journal of Pharmacology and Experimental Therapeutics 265, 16-23.
14. Brandrup E, Vanggaard T (1977). LSD treatment in a severe case of compulsive neurosis. Acta Psychiatrica Scandinavica 55, 127-141.
15. 1C receptor agonist. Journal of Pharmacology and Experimental Therapeutics 258, 891-896.
16. 2C receptor agonist, in two models of experimentally induced anxiety in healthy female volunteers. International Journal of Neuropsychopharmacology 2 (Suppl. 1), S136-S137.
17. Delgado PL, Moreno FA (1998). Hallucinogens, serotonin and obsessive-compulsive disorder. Journal of Psychoactive Drugs 30, 359-366.
18. Duman RS, Nakagawa S, Malberg J (2001). Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25, 830-844.
19. El Mansari M, Blier P (1997a). In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 36, 577-588.
20. El Mansari M, Blier P (1997b). Effect of a prolonged paroxetine treatment on the responsiveness of postsynaptic 5-HT receptors in the rat obitofrontal cortex. Society of Neuroscience, Abstract 23, 386.4.
21. 2A knockout mice. American Journal of Physiology: Gastrointestinal Liver Physiology 282, G877-G893.
22. Gingrich JA, Hen R (2001). Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 155, 1-10.
23. Goodman WK (1999). Obsessive-compulsive disorder: diagnosis and treament. Journal of Clinical Psychiatry 60 (Suppl. 18), 27-32.
24. 1A receptors. Journal of Neuroscience 18, 10150-10156.
25. 1A receptor agonist fesinoxan on rat 5-HT neurotransmission. European Neuropsychopharmacology 9, 427-440.
26. Hanes KR (1996). Serotonin, psilocybin, and body dysmorphic disorder: a case report. Journal of Clinical Psychopharmacology 16, 188-189.
27. Hayashi R, Tako K, Makishita H, Koyama J, Janagisawa N (1998). Efficacy of low-dose subcutaneous lisuride infusion in Parkinson's disease. Internal Medicine 37, 444-448.
28. Kaleli S, Aydin Y, Erel CT, Colgar U (2001). Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controllled randomized study. Fertility and Sterility 75, 718-723.
29. Leonard HL, Rapoport JL (1987). Relief of obsessive-compulsive symptoms by LSD and psilocin. American Journal of Psychiatry 144, 1239-1240.
30. Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981). Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73, 328-331.
31. Moreno FA, Delgado PL (1997). Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry 154, 1037-1038.
32. Nichols CD, Sanders-Bush E (2002). A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology 26, 634-642.
33. Rajkowska G, de Vos K, Pool CW, Roland PE, Zilles K, Uylings H (1998). 3-D Cytoarchitectonic parcellation of human orbitofrontal cortex, correlation with postmortem MRI. Society for Neuroscience, Abstract 24, 1165.
34. Rosecrans JA, Lovell RA, Freedman DX (1967). Effects of lysergic acid diethylamide on the metabolism of brain 5-hydroxytryptamine. Behavioral Pharmacology 16, 2011-2021.
35. 2C receptor knockout mice. Naunyn-Schmiedeberg's Archives of Pharmacology 361, 484-491.
36. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter Jr. LR (2002). Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Archives of General Psychiatry 59, 250-261.
37. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999). Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. Journal of Neuroscience 19, 5034-5043.
38. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94, 213-216.
39. Trulson ME, Jacobs BL (1977). Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat. Brain Research 132, 315-326.